Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Alison Stopeck(National Cancer Centre Japan), Ada Braun(National Cancer Centre Japan), Karim Fizazi(Université de Lille), Denise A. Yardley(Sarah Cannon), Tapan Maniar(Amgen (United States)), Paul Sieber(Lancaster General Hospital), Alexander Paterson, Lawrence I. Karsh(The Urology Center of Colorado), Katia Tonkin(National Cancer Centre Japan), Ingo Diel, Huei Wang(National Taiwan University), Janet E. Brown(University of Sheffield), Yasuhiro Fujiwara(Yokohama City University), Neal D. Shore(Carolina Urologic Research Center), Miguel Martín(Hospital General Universitario Gregorio Marañón), Jorge Arellano(Amgen (United States)), Jean-Jacques Body(National Cancer Centre Japan), Frank Kueppers, Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center)
Cited by 190
Related Papers
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k